Carcinomatous meningitis from solid tumors has not been investigated in detail in the Moroccan population. Therefore, we reviewed our experience with this disease to determine its clinical features and treatment outcomes in Moroccan patients. We performed a retrospective review of all patients with solid cancers admitted to the Military Hospital Moulay Ismail in Meknes, Morocco with carcinomatous meningitis between January 2011 and December 2017. A total of 12 patients were included. 5 were males and 7 were females. The median age was 54 years old (39 – 77 years old). The most frequent primary tumor was breast cancer (50%) and lung cancer (34%). The median time from initial cancer diagnosis to the development of carcinomatous meningitis was 6.9 months (0 – 49 months). The most common symptoms were headache (67%), nausea and vomiting (42%), and vision changes (34%). The diagnosis of CM was established by both CSF cytology and MRI in 25% of patients, by CSF cytology alone in 17%, and by MRI alone in 58%. One of the 12 patients received supportive care only. Chemotherapy was the only treatment for 50% of patients, 17% received radiotherapy alone, and 25% received both chemotherapy and radiotherapy. The median survival from the time of carcinomatous meningitis diagnosis was 9 weeks (2 – 29 weeks). Our results confirm the continued poor prognosis of carcinomatous meningitis in Moroccan patients with solid tumors as well. Further clinical trials are needed to improve therapeutic strategies including prophylactic approaches